The rare circulating tumor microemboli as a biomarker contributes to predicting early colorectal cancer recurrences after medical treatment

This study evaluated the rare circulating tumor microemboli (CTM) from liquid biopsy individually and together with circulating tumor cells (CTCs) and serum CEA/CA19-9 in a panel, on early prediction of colorectal cancer (CRC) recurrence. Stained CTCs/CTM were detected by a microfluidic chip-based automatic rare-cell imaging platform. ROC, AUC, Kaplan-Meier survival, and Cox proportional hazard models regarding 4 selected biomarkers were analyzed.

Source: Translational Research - August 7, 2023 Category: Research Authors: Yun-Jie Hao, Lu-Wey Chang, Chih-Yung Yang, Liang-Chuan Lo, Chien-Ping Lin, Yuan-Wei Jian, Jeng-Kai Jiang, Fan-Gang Tseng Source Type: research